ITRM20120121A1 - DERMOPROTECTIVE AND DERMO-BALANCING COMPOSITION. - Google Patents
DERMOPROTECTIVE AND DERMO-BALANCING COMPOSITION. Download PDFInfo
- Publication number
- ITRM20120121A1 ITRM20120121A1 IT000121A ITRM20120121A ITRM20120121A1 IT RM20120121 A1 ITRM20120121 A1 IT RM20120121A1 IT 000121 A IT000121 A IT 000121A IT RM20120121 A ITRM20120121 A IT RM20120121A IT RM20120121 A1 ITRM20120121 A1 IT RM20120121A1
- Authority
- IT
- Italy
- Prior art keywords
- oil
- composition according
- composition
- extract
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 98
- 239000000284 extract Substances 0.000 claims description 40
- 239000003921 oil Substances 0.000 claims description 26
- 235000019198 oils Nutrition 0.000 claims description 24
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 206010015150 Erythema Diseases 0.000 claims description 16
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 206010040882 skin lesion Diseases 0.000 claims description 11
- 231100000444 skin lesion Toxicity 0.000 claims description 11
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 230000003902 lesion Effects 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 10
- 239000000341 volatile oil Substances 0.000 claims description 10
- 235000013871 bee wax Nutrition 0.000 claims description 9
- 239000012166 beeswax Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 229940119170 jojoba wax Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000546188 Hypericum Species 0.000 claims description 7
- 231100000321 erythema Toxicity 0.000 claims description 7
- -1 jojoba oil Substances 0.000 claims description 7
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 6
- 240000007551 Boswellia serrata Species 0.000 claims description 6
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 6
- 239000004863 Frankincense Substances 0.000 claims description 6
- 230000007794 irritation Effects 0.000 claims description 6
- 239000002304 perfume Substances 0.000 claims description 6
- 230000002745 absorbent Effects 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 206010006797 Burns first degree Diseases 0.000 claims description 4
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 4
- 244000178870 Lavandula angustifolia Species 0.000 claims description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 4
- 240000003553 Leptospermum scoparium Species 0.000 claims description 4
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 239000001102 lavandula vera Substances 0.000 claims description 4
- 235000018219 lavender Nutrition 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 239000007762 w/o emulsion Substances 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 229940059958 centella asiatica extract Drugs 0.000 claims description 3
- 238000004040 coloring Methods 0.000 claims description 3
- 229940075000 frankincense extract Drugs 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 241000256844 Apis mellifera Species 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940005582 gotu kola extract Drugs 0.000 claims description 2
- 229940081859 myrrh extract Drugs 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 26
- 230000006378 damage Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 9
- 240000007311 Commiphora myrrha Species 0.000 description 8
- 235000006965 Commiphora myrrha Nutrition 0.000 description 8
- 235000007265 Myrrhis odorata Nutrition 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008158 vegetable oil Substances 0.000 description 6
- 244000146462 Centella asiatica Species 0.000 description 5
- 235000004032 Centella asiatica Nutrition 0.000 description 5
- 206010021639 Incontinence Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 244000141009 Hypericum perforatum Species 0.000 description 3
- 235000021324 borage oil Nutrition 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010051814 Eschar Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000544 hyperemic effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000125300 Argania sideroxylon Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010037867 Rash macular Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000010478 argan oil Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010474 borage seed oil Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 229930013686 lignan Chemical class 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000009329 organic farming Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Cosmetics (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Finger-Pressure Massage (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Turbine Rotor Nozzle Sealing (AREA)
Description
"COMPOSIZIONE DERMOPROTETTIVA E DERMOEQUILIBRANTE" "DERMO-PROTECTIVE AND DERMO-BALANCING COMPOSITION"
DESCRIZIONE DESCRIPTION
STATO DELLA TECNICA ANTERIORE STATE OF THE PRIOR ART
Il trattamento delle lesioni cutanee e delle ferite rappresenta uno dei problemi più antichi per l’uomo e sin dall’antichità si sono cercati rimedi per facilitare la riparazione del tessuto cutaneo con conseguente ripristino di una cute sana ed elastica. The treatment of skin lesions and wounds represents one of the oldest problems for man and since ancient times remedies have been sought to facilitate the repair of the skin tissue with consequent restoration of a healthy and elastic skin.
Un particolare tipo di lesioni à ̈ quello rappresentato da lesioni cutanee che possono interessare anche il tessuto sottostante e in cui non sono presenti ferite aperte, come irritazioni, eritemi, ustioni di primo grado, fasi di cicatrizzazione di ferite in cui la cute à ̈ rimarginata o lesioni causate da pressione come ad esempio lesioni da decubito di fase I. Nel caso di lesioni causate da pressione, come per le piaghe da decubito o nelle ustioni di primo grado oppure nel processo di rimarginazione di ferite, ulcere, ustioni, cicatrici, che interessano la cute e il tessuto sottostante, à ̈ di fondamentale importanza cercare di evitare danni localizzati in queste zone di maggiore sensibilità . A particular type of injury is represented by skin lesions that can also affect the underlying tissue and in which there are no open wounds, such as irritation, erythema, first degree burns, wound healing phases in which the skin is healed. or pressure sores such as stage I pressure sores. In the case of pressure sores, such as pressure sores or first degree burns or in the healing process of wounds, ulcers, burns, scars, which affect the skin and the underlying tissue, it is of fundamental importance to try to avoid localized damage in these areas of greatest sensitivity.
In questi casi sarebbe auspicabile trattare la cute della regione interessata in modo da impedire che la situazione di lesione anche lieve o di guarigione parziale presente, peggiori portando alla formazione di nuove lesioni. In these cases it would be desirable to treat the skin of the affected region in order to prevent the situation of even slight injury or partial healing present, worsening leading to the formation of new lesions.
Nel caso delle lesioni da pressione, come ad esempio le piaghe da decubito, si tratta di aree di danno localizzate della cute e del tessuto sottostante causate dalla pressione, dallo stiramento o dalla pressione subita in tali aree a causa, normalmente, della impossibilità del paziente a muoversi spostando le aree di pressione nel tempo ed evitando quindi i danni causati da una prolungata assenza di microcircolazione associata pressione e dallo sfregamento in regioni localizzate. In the case of pressure sores, such as bedsores, these are localized areas of damage to the skin and underlying tissue caused by the pressure, stretching or pressure experienced in these areas due, usually, to the patient's inability to move by moving the areas of pressure over time and thus avoiding the damage caused by a prolonged absence of microcirculation associated with pressure and by rubbing in localized regions.
La lesione da decubito à ̈ un’alterazione tessutale a evoluzione necrotica che interessa i tessuti molli interposti fra la superficie d’appoggio e l’osso sottostante. The decubitus lesion is a tissue alteration with necrotic evolution that affects the soft tissues interposed between the support surface and the underlying bone.
Tale patologia deriva dal decubito prolungato in posizione obbligata che, comprimendo e stirando i tessuti, li rende ischemici. This pathology derives from prolonged decubitus in a forced position which, by compressing and stretching the tissues, makes them ischemic.
La lesione insorge in sedi particolarmente predisposte ed à ̈ favorita da fenomeni locali o generali. The lesion occurs in particularly predisposed sites and is favored by local or general phenomena.
Le sedi più colpite sono le regioni sacrali, calcaneari e sovratrocanteriche. The most affected sites are the sacral, calcaneal and supratrocanteric regions.
Nei casi più gravi qualsiasi area sottostante una superficie ossea può essere interessata. In severe cases, any area underneath a bony surface can be affected.
Si distinguono quattro “stadi†o “tipi†anatomopatologici e clinici. There are four anatomopathological and clinical â € œstagesâ € or â € œtypesâ €.
STADIO o TIPO I STADIUM or TYPE I
Eritema persistente con cute intatta, preannuncia l’ulcera cutanea. Persistent erythema with intact skin, heralds skin ulcer.
STADIO o TIPO II STADIUM or TYPE II
Perdita a spessore parziale di tessuto cutaneo coinvolgente l’epidermide, il derma o entrambi. L’ulcera à ̈ superficiale e si presenta come abrasione o bolla sottile. Partial thickness loss of skin tissue involving the epidermis, the dermis or both. The ulcer is superficial and appears as an abrasion or a thin blister.
STADIO o TIPO III STAGE or TYPE III
Perdita a tutto spessore della cute che implica il danno o la necrosi del tessuto sottocutaneo fino alla sottostante fascia muscolare, senza oltrepassarla. All’inizio à ̈ presente un’escara, dopo la sua rimozione rimane un’ulcera che si presenta come un cratere profondo. Full thickness loss of the skin that implies damage or necrosis of the subcutaneous tissue up to the underlying muscle band, without going beyond it. At the beginning there is an eschar, after its removal there remains an ulcer which looks like a deep crater.
STADIO o TIPO IV STADIUM or TYPE IV
Perdita a tutto spessore del tessuto cutaneo, con estesa distruzione e necrosi dei tessuti, muscoli, ossa e strutture di supporto (tendini, capsule articolar). La lesione à ̈ coperta da un’escara. Dopo la sua rimozione resta una profonda ulcera che può essere sottominata e presentare tragitti fistolosi. Full thickness loss of skin tissue, with extensive destruction and necrosis of tissues, muscles, bones and supporting structures (tendons, joint capsules). The lesion is covered by an eschar. After its removal, a deep ulcer remains which can be undermined and have sinus tracts.
Il paziente a rischio per lesioni da decubito presenta come fattore di rischio tutte quelle condizioni in cui si ha un’alterazione della mobilità che comporti forze compressive, forze di stiramento e forze di frizione agenti sulla cute. The patient at risk for pressure ulcers presents as a risk factor all those conditions in which there is an alteration of mobility that involves compressive forces, stretching forces and friction forces acting on the skin.
Inoltre, in caso d’immobilità , esistono ulteriori fattori noti predisponesti alla progressione delle lesioni quali la malnutrizione, l’incontinenza, disturbi cognitivi, disidratazione, malnutrizione, età avanzata, infezioni, obesità , estrema magrezza, ischemia o ipossia eccetera. Furthermore, in case of immobility, there are other known factors predisposing to the progression of the lesions such as malnutrition, incontinence, cognitive disorders, dehydration, malnutrition, advanced age, infections, obesity, extreme thinness, ischemia or hypoxia, etc.
Tali lesioni si possono ampiamente prevenire e limitare con una cura medica appropriata. Such injuries can be largely prevented and limited with appropriate medical care.
La cura delle lesioni da decubito ha anche risvolti socio-economici non trascurabili, ad esempio à ̈ molto comune nella popolazione umana e animale (ad esempio mammiferi) la presenza di piaghe croniche (ulcere diabetiche e da stasi venosa, piaghe da decubito ecc.); il costo medio per il trattamento dei pazienti à ̈ molto elevato, e, nel caso di pazienti umani, tale costo incide in maniera non trascurabile sui sistemi sanitari nazionali. The treatment of pressure sores also has socio-economic implications that are not negligible, for example the presence of chronic sores (diabetic and venous stasis ulcers, pressure sores, etc.) is very common in the human and animal population (for example mammals). ; the average cost of treating patients is very high, and in the case of human patients, this cost has a not negligible impact on national health systems.
Secondo una buona pratica medica, al fine di evitare questo tipo di lesione o di limitarne l’insorgenza, sono opportuni accorgimenti preventivi di cura e manipolazione del paziente uniti alla cura immediata delle condizioni di tipo I per limitare al massimo la progressione della lesione in stadi più invasivi e difficili da recuperare. According to good medical practice, in order to avoid this type of injury or to limit its onset, preventive care and manipulation of the patient together with the immediate treatment of type I conditions are appropriate to limit the progression of the lesion as much as possible. stages more invasive and difficult to recover.
Spesso, soprattutto quando à ̈ necessario un trattamento frequente o prolungato, o quando sono trattati soggetti già sottoposti a vari trattamenti con farmaci o quando le condizioni del paziente presuppongono posizioni corporee che non facilitano la rigenerazione del tessuto e la risoluzione della lesione cutanea, à ̈ auspicabile l’uso di prodotti di origine naturale. Di conseguenza sarebbe preferibile evitare l’uso di farmaci, utilizzando un prodotto comunque di buona efficacia per il trattamento delle lesioni in cui la cute e anche i tessuti sottostanti possano essere interessati, senza presenza di ferite aperte. Inoltre, in fase preventiva non à ̈ indicato l’impiego di: alcol etilico o di prodotti a base di alcol poiché sostanze di questo tipo, benché disinfettanti, provocano la disidratazione della cute. È preferibile anche evitare l’utilizzo di paste molto dense che sono difficili da rimuovere senza l’uso di un detergente e polveri che riducono il film idrolipidico della cute. Often, especially when frequent or prolonged treatment is required, or when subjects already undergoing various drug treatments are treated or when the patient's condition requires body positions that do not facilitate tissue regeneration and resolution of the skin lesion, is the use of products of natural origin is desirable. Consequently, it would be preferable to avoid the use of drugs, using a product of good efficacy for the treatment of lesions in which the skin and also the underlying tissues may be affected, without the presence of open wounds. Furthermore, in the preventive phase, the use of: ethyl alcohol or alcohol-based products is not recommended since substances of this type, although disinfectants, cause dehydration of the skin. It is also preferable to avoid the use of very dense pastes that are difficult to remove without the use of a detergent and powders that reduce the hydrolipidic film of the skin.
SOMMARIO DELL'INVENZIONE SUMMARY OF THE INVENTION
La presente invenzione riguarda una composizione innovativa per la cura o la prevenzione di lesioni cutanee che non implicano la presenza di ferite aperte o nella prevenzione o rallentamento di aggravamenti delle stesse, comprendente, come principi attivi, cera d’api, estratto d’incenso e/o di mirra, estratto di centella asiatica, estratto d’iperico, olio di jojoba, ed eccipienti. Tale composizione, si à ̈ rivelata, per la scelta dei principi attivi, dotata di una forte azione dermoequilibrante e dermoprotettiva e si à ̈ rivelata di grande efficacia nella cura di lesioni cutanee elementari o primarie, e cioà ̈ di quelle lesioni che non implicano la presenza di ferite aperte. The present invention relates to an innovative composition for the treatment or prevention of skin lesions that do not involve the presence of open wounds or for the prevention or slowing of aggravation of the same, including, as active ingredients, beeswax, extract of frankincense and / or myrrh, gotu kola extract, hypericum extract, jojoba oil, and excipients. This composition, due to the choice of active ingredients, has proved to be endowed with a strong dermo-balancing and dermoprotective action and has proved to be highly effective in the treatment of elementary or primary skin lesions, and that is, those lesions that do not involve the presence of open wounds.
La selezione delle componenti descritta nella presente descrizione, à ̈ risultata essere assolutamente atossica e ben tollerata e ha permesso di realizzare una composizione che ha mostrato un insieme di effetti, protettivi, emollienti e curativi, efficaci nella cura o nella prevenzione delle irritazioni cutanee così come nella prevenzione di possibili aggravamenti delle stesse (ad esempio prevenzione del passaggio da lesioni da decubito di tipo I a lesioni da decubito di tipo II e reversione di lesioni da decubito di tipo I a cute sana). The selection of the components described in this description was found to be absolutely non-toxic and well tolerated and made it possible to create a composition that has shown a set of protective, emollient and curative effects, effective in the treatment or prevention of skin irritations as well. as in the prevention of possible aggravations of the same (for example prevention of the transition from pressure ulcers type I to pressure ulcers type II and reversion of pressure ulcers type I to healthy skin).
La composizione dell’invenzione si à ̈ rivelata essere più efficace, in test comparativi, nella cura o la prevenzione di lesioni cutanee che non implicano la presenza di ferite aperte o nella prevenzione o rallentamento di aggravamenti delle stesse rispetto a composizioni comunemente utilizzate in questi casi come ad esempio pomate o creme comprendenti ossido di zinco. The composition of the invention has proved to be more effective, in comparative tests, in the treatment or prevention of skin lesions that do not involve the presence of open wounds or in the prevention or slowing of aggravations of the same than compositions commonly used in these cases such as ointments or creams including zinc oxide.
Una cute ben curata à ̈ meno facilmente lesionabile e guarisce più velocemente di una in cattive condizioni, gli inventori hanno realizzato un prodotto preventivo in grado di mantenere l’integrità del film idrolipidico cutaneo, che grazie alle sue proprietà anti-sfregamento e anti-attrito esplica un effetto barriera e come conseguenza provoca indirettamente i seguenti effetti: A well cared for skin is less easily injured and heals faster than one in poor condition, the inventors have created a preventive product capable of maintaining the integrity of the skin hydrolipidic film, which thanks to its anti-rubbing and anti- friction exerts a barrier effect and as a consequence indirectly causes the following effects:
- azione idratante/emolliente - moisturizing / emollient action
- azione lenitiva anti-infiammatoria - soothing anti-inflammatory action
- azione migliorativa del microcircolo - improving action of the microcirculation
che sono azioni auspicabili in genere e particolarmente utili nei casi di incontinenza o di immobilità dell’individuo da trattare. which are generally desirable actions and particularly useful in cases of incontinence or immobility of the individual to be treated.
DESCRIZIONE DETTAGLIATA DELL'INVENZIONE DETAILED DESCRIPTION OF THE INVENTION
La composizione dermoequilibrante e dermoprotettiva della presente invenzione, comprende, come principali componenti attive fondamentali, cera d’api, estratto di incenso e/o di mirra, estratto di centella asiatica, estratto di iperico e olio di jojoba. Tale composizione, grazie ai suoi effetti protettivi, emollienti e curativi, si à ̈ dimostrata particolarmente efficace nella cura o delle lesioni cutanee che non implicano la presenza di ferite aperte, nella prevenzione di tale tipo di lesioni o irritazioni cutanee e così come nella prevenzione o nel rallentamento di evoluzioni di tali lesioni a stadi più gravi. The dermo-balancing and dermal-protective composition of the present invention includes, as main active components, beeswax, frankincense and / or myrrh extract, centella asiatica extract, hypericum extract and jojoba oil. This composition, thanks to its protective, emollient and curative effects, has proven to be particularly effective in the treatment of skin lesions that do not involve the presence of open wounds, in the prevention of this type of skin lesions or irritation and as well as in the prevention or in slowing the evolution of such injuries to more serious stages.
Per lesioni cutanee che non implicano la presenza di ferite aperte, secondo la presente descrizione, sono intese quelle lesioni in cui lo strato superficiale della cute, e gli strati sottostanti, pur non essendo feriti, sono particolarmente fragili, irritati e danneggiati. By skin lesions which do not imply the presence of open wounds, according to the present description, are meant those lesions in which the superficial layer of the skin, and the underlying layers, although not injured, are particularly fragile, irritated and damaged.
Esempi non limitanti di questo tipo di lesioni sono rappresentati da ustioni di primo grado, lesioni da decubito di primo grado, lesioni da pressione, arrossamenti, ferite o ustioni neo cicatrizzate, irritazioni, eritemi. Non-limiting examples of this type of injury are first degree burns, first degree bedsores, pressure injuries, redness, newly healed wounds or burns, irritation, erythema.
In una forma di realizzazione dell’invenzione, la composizione qui descritta à ̈ efficace nel trattamento di lesioni da pressione come piaghe da decubito di tipo I promuovendo una regressione da tale stadio a cute non iperemica, o rallentando o prevenendo l’evoluzione da piaghe di tipo I a piaghe di tipo II rispetto a piaghe di tipo I trattate ad esempio con composizioni a base di ossido di zinco, comunemente utilizzato per questo tipo di trattamenti. In one embodiment of the invention, the composition described herein is effective in the treatment of pressure sores such as type I bedsores by promoting regression from that stage to non-hyperemic skin, or by slowing or preventing evolution from type I sores to type II sores compared to type I sores treated for example with compositions based on zinc oxide, commonly used for this type of treatment.
Secondo l’invenzione la composizione qui descritta può essere efficace anche nella prevenzione dell’insorgenza di arrossamenti dovuti ad incontinenza urinaria e fecale patologica e non. Tali tipi di incontinenza sono ad esempio fisiologici nei lattanti e nei bambini fino ai 2 o 3 anni e sono patologici, normalmente, dopo tale età . According to the invention, the composition described here can also be effective in preventing the onset of redness due to pathological and non-pathological urinary and fecal incontinence. Such types of incontinence are, for example, physiological in infants and children up to 2 or 3 years of age and are normally pathological after this age.
In questa forma di realizzazione la composizione qui descritta potrà essere utilizzata a scopo preventivo sia in quanto tale, sia incorporata in un dispositivo quale una salvietta, un pannolino o tampone assorbente e simili. In this embodiment, the composition described here can be used for preventive purposes either as such, or incorporated in a device such as a wipe, an absorbent diaper or pad and the like.
Secondo la presente invenzione, in accordo con la letteratura scientifica incenso e mirra sono resine di origine vegetale secrete dalle piante fisiologicamente o, più spesso, in risposta a traumi meccanici (incisioni, tagli) o ad uno stress (attacco di patogeni) costituite da un gruppo complesso di sostanze solide, traslucide, occasionalmente liquide, insolubili in acqua, solubili in alcool, acetone, etere e cloroformio According to the present invention, in accordance with the scientific literature, incense and myrrh are resins of vegetable origin secreted by plants physiologically or, more often, in response to mechanical trauma (incisions, cuts) or to a stress (attack of pathogens) consisting of a complex group of solid, translucent, occasionally liquid substances, insoluble in water, soluble in alcohol, acetone, ether and chloroform
Tali resine contengono miscele complesse di, alcoli o acidi alifatici, lignani, acidi resinici, resinotannoli, esteri e reseni (che traggono origine da processi di polimerizzazione e di ossidazione di terpeni degli oli essenziali) e altro. These resins contain complex mixtures of alcohols or aliphatic acids, lignans, resin acids, resinotannols, esters and resens (which originate from polymerization and oxidation processes of essential oil terpenes) and more.
Dal punto di vista chimico nelle resine si trovano molti componenti diversi: alcoli o acidi alifatici a diversa lunghezza della catena carboniosa acidi aromatici liberi, acidi resinici, alcoli monoterpenici, alcoli, diterpenici, alcoli triterpenici, resinoli, composti fenolici appartenenti alla famiglai degli steroli, ecc. From the chemical point of view in the resins there are many different components: alcohols or aliphatic acids at different length of the carbon chain free aromatic acids, resin acids, monoterpenic alcohols, alcohols, diterpene alcohols, triterpene alcohols, resinols, phenolic compounds belonging to the sterol family, etc.
Secondo la presente invenzione la composizione comprenderà incenso, mirra, in forma triturata (o polverizzata) e/o in forma di estratto o loro miscele. According to the present invention, the composition will include incense, myrrh, in shredded (or pulverized) form and / or in extract form or mixtures thereof.
Il tecnico del settore saprà comunque identificare ulteriori resine oltre a quelle qui indicate semplicemente per analogia senza alcun utilizzo di attività inventiva. The skilled in the art will in any case be able to identify further resins in addition to those indicated here simply by analogy without using any inventive step.
La composizione potrà quindi contenere, come già detto, tali resine in forma polverizzata, granulata, o in forma di estratto secco e/o di estratto liofilizzato e/o frazioni di tali estratti che saranno poi sospese in olio di origine vegetale e/o minerale In una particolare forma di realizzazione la componente secca (i grani di incenso/mirra) sarà risospesa, a formare un estratto oleoso quindi, ad una percentuale tra lo 0,01 ed il 10% in peso rispetto all’olio, in olio idoneo all’uso topico. The composition may therefore contain, as already mentioned, these resins in pulverized, granulated form, or in the form of dry extract and / or lyophilized extract and / or fractions of these extracts which will then be suspended in oil of vegetable and / or mineral origin. In a particular embodiment the dry component (the grains of frankincense / myrrh) will be resuspended, to form an oily extract therefore, at a percentage between 0.01 and 10% by weight with respect to the oil, in suitable oil for topical use.
Tale olio potrà essere olio di orgine vegetale (semi di girasole, olio di oliva, argan noccioli, jojoba, mandorle dolci, macadamia noci, borragine semi, enothera semi, germe di grano semi di lino) o di origine minerale (paraffine liquide) o loro miscele. This oil may be vegetable oil (sunflower seeds, olive oil, argan kernels, jojoba, sweet almonds, macadamia nuts, borage seeds, enothera seeds, wheat germ, linseed) or of mineral origin (liquid paraffins) or their blends.
Vantaggiosamente gli estratti d’incenso e/o di mirra, oltre a coadiuvare la realizzazione di un effetto barriera sulla cute da parte della composizione qui descritta, permettono anche alle altre componenti della composizione di rimanere adese più a lungo in contatto sulla cute irritata, impedendone un dilavamento veloce da parte di liquidi biologici (urine, feci, sudore), permettendo quindi alla composizione di esplicare più a lungo ed al meglio il suo effetto. Advantageously, the extracts of incense and / or myrrh, in addition to assisting in the creation of a barrier effect on the skin by the composition described here, also allow the other components of the composition to remain adhered for longer in contact with the irritated skin, preventing a quick washout by biological liquids (urine, faeces, sweat), thus allowing the composition to exert its effect longer and better.
L’estratto oleoso come qui descritto sarà presente ad una percentuale tra il 40 ed il 60% in peso della composizione qui descritta. The oily extract as described here will be present at a percentage between 40 and 60% by weight of the composition described here.
Questo significa che l’estratto oleoso d’incenso e/o mirra potrà essere presente nella miscela ad una concentrazione pari a circa il 40, il 41, il 42, il 43, il 44, il 45, il 46, il 47, il 48, il 49, il 50, il 51, il 52, il 53, il 54, il 55, il 56, il 57, il, 58, il 59 o il 60% in peso della composizione. This means that the oily extract of frankincense and / or myrrh may be present in the mixture at a concentration equal to about 40, 41, 42, 43, 44, 45, 46, 47 , 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60% by weight of the composition.
Ovviamente sono compresi anche i numeri decimali tra ciascun numero intero indicato. Obviously, the decimal numbers between each indicated integer are also included.
La composizione comprenderà anche un estratto di centella asiatica (foglie), in una forma particolare dell’invenzione questo potrà essere un estratto oleoso di foglie, tale estratto sarà normalmente presente ad una concentrazione tra il 10 ed il 20% in peso della composizione, e cioà ̈ circa il 10, l’11, il 12, il 13, il 14, il 15, il 16, il 17, il 18, il 19, il 20% in peso. Anche in questo caso sono compresi i numeri decimali tra ciascun numero intero indicato. A titolo esemplificativo, la percentuale totale di centella asiatica nell’estratto sopra descritto potrà essere compresa tra lo 0.1 ed il 10% in peso rispetto all’olio. The composition will also include an extract of gotu kola (leaves), in a particular form of the invention this could be an oily extract of leaves, this extract will normally be present at a concentration between 10 and 20% by weight of the composition, and that is about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20% by weight. Also in this case the decimal numbers are included between each integer indicated. By way of example, the total percentage of gotu kola in the extract described above may be between 0.1 and 10% by weight with respect to the oil.
In tutte le forme di realizzazione qui descritte gli “oli vegetali†compresi negli estratti saranno normalmente oli di semi o di frutto e potranno essere uno degli oli vegetali sopra indicati o una loro miscela. In all the embodiments described herein, the "vegetable oils" included in the extracts will normally be seed or fruit oils and may be one of the vegetable oils indicated above or a mixture thereof.
Un altro ingrediente attivo della composizione secondo l’invenzione à ̈ rappresentato da estratto di iperico (di fiori e/o foglie e/o peduncolo), che potrà essere un estratto oleoso Another active ingredient of the composition according to the invention is represented by hypericum extract (of flowers and / or leaves and / or peduncle), which could be an oily extract
Tale estratto sarà normalmente presente ad una concentrazione tra il 10 ed il 20% in peso della composizione, e cioà ̈ circa il 10, l’11, il 12, il 13, il 14, il 15, il 16, il 17, il 18, il 19, il 20% in peso. Anche in questo caso sono compresi i numeri decimali tra ciascun numero intero indicato. A titolo esemplificativo, la percentuale totale d’iperico perforato nell’estratto sopra descritto potrà essere compresa tra lo 0,001 ed il 10% rispetto all’olio. This extract will normally be present at a concentration between 10 and 20% by weight of the composition, i.e. about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20% by weight. Also in this case the decimal numbers are included between each integer indicated. By way of example, the total percentage of hypericum perforated in the extract described above may be between 0.001 and 10% with respect to the oil.
Gli oli potranno essere uno o più degli oli vegetali sopra indicati. The oils may be one or more of the vegetable oils indicated above.
La composizione secondo l’invenzione comprenderà anche olio di jojoba, in particolare potrà comprendere olio di semi di jojoba. Tale olio sarà compreso ad una concentrazione tra il 5 ed il 15% in peso della composizione, e cioà ̈ circa il 5, il 6, il 7, l’8 il 9, il 10, l’11, il 12, il 13, il 14, il 15 in peso della composizione. Sono ovviamente compresi anche i numeri decimali tra ciascun numero intero indicato. The composition according to the invention will also include jojoba oil, in particular it may include jojoba seed oil. This oil will be included at a concentration between 5 and 15% by weight of the composition, and that is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 by weight of the composition. Obviously, the decimal numbers between each indicated integer are also included.
Infine, la composizione comprenderà come ingrediente attivo cera d’api ad una concentrazione compresa tra il 3 e il 7 % e cioà ̈ circa il 3, il 4, il 5, il 6, il 7% in peso della composizione, compresi i numeri decimali tra un numero intero e il successivo. Finally, the composition will include as an active ingredient beeswax at a concentration between 3 and 7% and that is approximately 3, 4, 5, 6, 7% by weight of the composition, including decimal numbers between one whole number and the next.
In una forma di realizzazione detta cera d’api à ̈ cera gialla del favo di Apis mellifera. In one embodiment called beeswax it is yellow wax from the honeycomb of Apis mellifera.
Tutti i principi attivi vegetali utilizzati o la maggior parte di essi saranno preferibilmente ottenuti da agricolture biologiche. All or most of the plant active ingredients used will preferably be obtained from organic farming.
In tutti i casi in cui à ̈ sopra indicato l’uso di olio vegetale, come olio di semi, per la preparazione degli estratti, tale olio potrà essere anche sotto forma di emulsione olio in acqua, acqua in olio o anche olio in gel o gel in olio. In all cases where the use of vegetable oil, such as seed oil, for the preparation of extracts is indicated above, this oil can also be in the form of an oil-in-water, water-in-oil or even oil-gel emulsion. or gel in oil.
Non solo gli estratti potranno essere in forma di emulsione ma anche la composizione stessa potrà essere formulata come emulsione. Si definisce una emulsione “olio in acqua†una emulsione in cui la fase disperdente à ̈ di tipo acquoso e la fase dispersa à ̈ di tipo oleoso mentre nel caso contrario si parla di emulsione acqua in olio. Not only the extracts can be in the form of an emulsion but also the composition itself can be formulated as an emulsion. An “oil in water” emulsion is defined as an emulsion in which the dispersing phase is of the aqueous type and the dispersed phase is of the oily type, while in the opposite case it is referred to as a water-in-oil emulsion.
La composizione potrà ulteriormente comprendere uno o più eccipienti idonei alla realizzazione della forma finale desiderata che potrà essere ad esempio come emulsione olio in acqua, emulsione acqua in olio, olio in gel o gel in olio, emulsioni multiple, spray, e formulazioni anidre (pomata, gel, pasta, crema, unguento). The composition may further comprise one or more excipients suitable for the realization of the desired final form which may be for example as an oil in water emulsion, water in oil emulsion, oil gel or gel in oil, multiple emulsions, sprays, and anhydrous formulations (ointment , gel, paste, cream, ointment).
Tali eccipienti potranno essere, ad esempio, emulsionanti (cetearil alcol, cetearil glucoside, olio di ricino idrogenato), additivi reologici, antiossidanti (come ad esempio vitamine, tocoferoli o altri antiossidanti noti nel settore). Such excipients may be, for example, emulsifiers (cetearyl alcohol, cetearyl glucoside, hydrogenated castor oil), rheological additives, antioxidants (such as vitamins, tocopherols or other antioxidants known in the field).
L’agente emulsionante potrà essere un tensioattivo, che abbassando la tensione interfacciale diminuisce l'energia libera del sistema; in alternativa, si possono utilizzare anche sostanze non tensioattive, quali la gomma arabica, la gelatina, colloidi idrofili o polveri finemente suddivise (ad es., talco). In una forma di realizzazione gli eccipienti potranno essere presenti ad una concentrazione complessiva in peso compresa tra il 3 e l’8%, tale concentrazione essendo ovviamente indicativa, tenendo conto che comunque il tecnico del settore saprà adattare la concentrazione degli eccipienti necessari secondo la forma di realizzazione che intende preparare senza aggiunta di attività inventiva. The emulsifying agent may be a surfactant, which by lowering the interfacial tension decreases the free energy of the system; alternatively, non-surfactant substances can also be used, such as gum arabic, gelatin, hydrophilic colloids or finely divided powders (eg talc). In one embodiment, the excipients may be present at an overall concentration by weight between 3 and 8%, this concentration obviously being indicative, taking into account that the skilled in the art will be able to adapt the concentration of the necessary excipients according to the embodiment intending to prepare without adding inventive step.
Inoltre la composizione potrà comprendere agenti profumanti e/o coloranti che ne rendano gradevole l’odore, come ad esempio uno o più oli essenziali come ad esempio olio essenziale di lavanda, olio essenziale di melaleuca, limone, menta, arancio, e/o agenti coloranti che permettano, ad esempio, di riconoscere facilmente le zone di applicazione della composizione, la colorazione essendo ad esempio temporanea in modo tale da non interferire con altre, successive, applicazioni della composizione. Furthermore, the composition may include perfuming agents and / or dyes that make the smell pleasant, such as one or more essential oils such as lavender essential oil, tea tree essential oil, lemon, mint, orange, and / or coloring agents which allow, for example, to easily recognize the areas of application of the composition, the coloring being for example temporary so as not to interfere with other subsequent applications of the composition.
In una forma di realizzazione detti agenti coloranti e/o profumanti sono compresi ad una concentrazione complessiva in peso tra lo 0,001 e il 3%. In one embodiment said coloring and / or perfuming agents are comprised at an overall concentration by weight between 0.001 and 3%.
Per “concentrazione complessiva in peso†s’intende la concentrazione in peso nella composizione della somma dei vari eccipienti o la concentrazione in peso nella composizione della somma dei vari agenti profumanti e/o coloranti presenti nella composizione. By "total concentration by weight" we mean the concentration by weight in the composition of the sum of the various excipients or the concentration by weight in the composition of the sum of the various perfuming agents and / or coloring agents present in the composition.
Come già indicato sopra, la composizione dell’invenzione à ̈ una composizione per uso topico che potrà essere realizzata in forma di emulsione olio in acqua, emulsione acqua in olio, emulsioni multiple, spray, e formulazioni anidre (pomata, unguento, gel, pasta, crema, spray,) secondo tecniche comunemente utilizzate nel settore. La formulazione qui indicata come “spray†potrà essere una formulazione anidra o anche una formulazione in emulsione, la forma con erogatore nebulizzante permettendo anche auto applicazioni in zone più difficili da raggiungere (come ad esempio la schiena), utile in tutti quei casi in cui la formulazione à ̈ utilizzata, ad esempio, per alleviare arrossamenti solari, eritemi, o irritazioni cutanee di vario genere. As already indicated above, the composition of the invention is a composition for topical use that can be made in the form of an oil-in-water emulsion, a water-in-oil emulsion, multiple emulsions, sprays, and anhydrous formulations (ointment, ointment, gel, paste, cream, spray,) according to techniques commonly used in the sector. The formulation indicated here as â € œsprayâ € could be an anhydrous formulation or even an emulsion formulation, the form with nebulizing dispenser also allowing self-application in more difficult to reach areas (such as the back), useful in all those cases in which the formulation is used, for example, to relieve solar redness, erythema, or skin irritations of various kinds.
Seguono esempi non limitativi di composizione secondo l’invenzione Non-limiting examples of composition according to the invention follow
Esempio di composizione 1 Composition example 1
Estratto oleoso d’incenso tra il 45 e il 55% Estratto oleoso di centella asiatica tra il 12 e il 18% Estratto oleoso di iperico tra il 12 e il 18% Olio di jojoba tra il 7 e il 13% Cera d’api tra il 3 e il 7% Triidrossistearina tra il 2 e il 6% Oily extract of incense between 45 and 55% Oily extract of gotu kola between 12 and 18% Oily extract of St. John's wort between 12 and 18% Jojoba oil between 7 and 13% Wax bees between 3 and 7% Trihydroxystearine between 2 and 6%
Tocoferolo tra lo 0,01 e l’1,5% Olio essenziale di melaleuca tra lo 0,01 e l’1% Tocopherol between 0.01 and 1.5% Tea tree essential oil between 0.01 and 1%
Esempio di composizione 2 Composition example 2
-Estratto oleoso di mirra tra il 45 e il 55% Estratto oleoso di centella asiatica tra il 12 e il 18% Estratto oleoso di iperico tra il 12 e il 18% Olio di borragine tra il 2 e il 10% Cera d’api tra il 3 e il 7% Silice colloidale tra il 2 e il 6% -Oily extract of myrrh between 45 and 55% Oily extract of gotu kola between 12 and 18% Oily extract of St. John's wort between 12 and 18% Borage oil between 2 and 10% Beeswax between 3 and 7% Colloidal silica between 2 and 6%
Tocoferolo tra lo 0,01 e l’1,5% Olio essenziale di lavanda tra lo 0,01 e l’2% Tocopherol between 0.01 and 1.5% Lavender essential oil between 0.01 and 2%
Esempio di composizione 3 Composition example 3
Estratto oleoso di mirra tra il 5 e il 15% Estratto oleoso di centella asiatica tra il 3 e il 10% Estratto oleoso di iperico tra il 3 e il 10% Olio di borragine tra il 2 e il 10% Cera d’api tra il 0.5 e il 5% Glucoside cetilstearilico tra il 2 e il 6% Alcool cetilstearilico tra il 2% e il 6% Gomma xanthan tra il 0.2 e l’ 1% Tocoferolo tra lo 0,01 e l’1,5% Olio essenziale di lavanda tra lo 0,01 e l’2% Olio essenziale di melaleuca tra lo 0.01% e lo 0.6% Oily extract of myrrh between 5 and 15% Oily extract of gotu kola between 3 and 10% Oily extract of St. John's wort between 3 and 10% Borage oil between 2 and 10% Beeswax between 0.5 and 5% Cetylstearyl glucoside between 2 and 6% Cetylstearyl alcohol between 2% and 6% Xanthan gum between 0.2 and 1% Tocopherol between 0.01 and 1.5% Lavender essential oil between 0.01 and 2% Tea tree essential oil between 0.01% and 0.6%
Acqua deionizzata tra il 40% ed il 60% Deionized water between 40% and 60%
La composizione dell’invenzione, quando realizzata in forma di unguento o emulsione olio in acqua, o di gel oleoso comprenderà gli estratti sopra descritti prevalentemente in forma di estratti oleosi in cui l’unico agente di sospensione à ̈ rappresentato da un olio vegetale o da una loro miscela, come ad esempio olio di semi di girasole, olio di semi di lino, olio di jojoba, olio di macadamia, olio di argan, olio di borragine semi, di enothera semi, di germe di grano o loro miscele. The composition of the invention, when made in the form of an ointment or oil-in-water emulsion, or an oily gel, will include the extracts described above mainly in the form of oily extracts in which the only suspension agent is represented by a vegetable oil. or from a mixture thereof, such as sunflower oil, linseed oil, jojoba oil, macadamia oil, argan oil, borage seed oil, enothera seed oil, wheat germ oil or their mixtures.
La composizione secondo la presente descrizione potrà essere realizzata in forma di composizione farmaceutica oppure di dispositivo medico o compresa in un dispositivo medico secondo una qualsiasi delle classi descritte nella Direttiva CEE 93/42 sui dispositivi medici (che comprende anche sostanze e non solo “dispositivi†nel senso meccanico del termine), o in qualsiasi forma secondo le disposizioni regolatorie del paese in cui tale composizione sarà prodotta. The composition according to this description may be made in the form of a pharmaceutical composition or a medical device or included in a medical device according to any of the classes described in the EEC Directive 93/42 on medical devices (which also includes substances and not only â € œdevicesâ € in the mechanical sense of the term), or in any form according to the regulatory provisions of the country in which this composition will be produced.
Tutti gli eccipienti sopra indicati saranno in forma farmaceuticamente accettabile nel caso di realizzazione di una composizione farmaceutica (quindi grado farmaceutico) e potranno esserlo anche nel caso di dispositivo medico. All the excipients indicated above will be in pharmaceutically acceptable form in the case of making a pharmaceutical composition (therefore pharmaceutical grade) and may also be so in the case of a medical device.
L’invenzione riguarda quindi anche dispositivi medici ad come ad esempio cerotti medicati, garze medicate, bende medicate, salviette medicate, tamponi assorbenti medicati, pannolini medicati e cioà ̈ cerotti, garze, bende, salviette, tamponi o pannolini che comprendono la o siano coperti almeno in parte dalla o siano imbevuti almeno in parte della composizione dell’invenzione descritta nella forma più appropriata. The invention therefore also relates to medical devices such as for example medicated plasters, medicated gauze, medicated bandages, medicated wipes, medicated absorbent pads, medicated diapers and that is, plasters, gauze, bandages, wipes, tampons or diapers which include or are covered at least in part by or are impregnated at least in part with the composition of the invention described in the most appropriate form.
Le garze potranno essere realizzate come garze grasse, così le bende ed i cerotti utilizzando la composizione realizzata in forma di unguento, pasta o crema ad esempio. Le salviette potranno essere imbevute della composizione in forma di emulsione di olio con acqua o gel, e i pannolini o i tamponi assorbenti potranno essere realizzati inserendo la composizione negli appositi strati noti nel settore per l’inserimento di composizioni protettive o anti irritanti. The gauze can be made as greasy gauze, as well as the bandages and plasters using the composition made in the form of ointment, paste or cream for example. The wipes can be soaked in the composition in the form of an oil emulsion with water or gel, and the diapers or absorbent pads can be made by inserting the composition into the appropriate layers known in the field for the insertion of protective or anti-irritant compositions.
Tali prodotti come ad esempio pannolini per infanti, tamponi assorbenti o comunemente “assorbenti†per donne e pannolini per incontinenza dell’adulto, sono comunemente utilizzati ad esempio nel settore relativo all’infanzia, nel settore femminile e nel settore geriatrico e il tecnico del settore saprà dove inserire la composizione qui descritta e quale sua forma di realizzazione sia quella più idonea senza bisogno di particolari insegnamenti e basandosi unicamente su tecniche convenzionali nel settore. Such products such as infant diapers, absorbent pads or commonly â € œabsorbentsâ € for women and adult incontinence diapers, are commonly used for example in the childhood sector, in the female sector and in the geriatric sector and skilled in the art will know where to insert the composition described here and which embodiment is the most suitable without the need for particular teaching and based solely on conventional techniques in the sector.
Tali dispositivi saranno applicabili sulla parte da trattare e/o da proteggere a scopo preventivo. These devices will be applicable on the part to be treated and / or protected for preventive purposes.
L’invenzione riguarda anche un metodo per la cura o per la prevenzione dell’insorgenza o dell’aggravamento di lesioni cutanee che non implichino la presenza di ferite aperte in cui tale metodo comprende una o più applicazioni della composizione dell’invenzione o del dispositivo medico che la comprende una o più volte al dì sulla parte interessata. The invention also relates to a method for the treatment or prevention of the onset or aggravation of skin lesions that do not involve the presence of open wounds in which this method includes one or more applications of the composition of the invention or the medical device that includes it once or more times a day on the affected part.
L’applicazione della composizione, ad esempio, potrà essere ripetuta ogni qualvolta se ne presenti la necessità (ad esempio ad ogni cambio di pannolino nel caso della prevenzione di arrossamenti legati all’incontinenza) o una, due, tre, quattro o più volte al giorno in generale. The application of the composition, for example, can be repeated whenever the need arises (for example at each diaper change in the case of the prevention of redness related to incontinence) or one, two, three, four or more times a day in general.
ESEMPI EXAMPLES
1. SAGGIO DI IRRITAZIONE CUTANEA MEDIANTE “PATCH TEST†1. TEST FOR SKIN IRRITATION USING â € œPATCH TESTâ €
Sono stati reclutati 20 volontari sani di entrambi i sessi di età compresa tra i 18 e i 60 anni. Il campione à ̈ stato posto in Finn Chambers di alluminio (Bracco) che sono state applicate sulla cute del dorso e/o su cerotti porosi che sono stati applcati sulla cute dell’avambraccio. L’applicazione del prodotto sulla cute ha avuto una durata di 24 ore. Le reazioni cutanee sono state valutate clinicamente 30 minuti e 24 ore dopo rimozione della Finn Chamber e dopo 30 minuti e 24 ore dopo rimozione del cerotto poroso e sono state interpretate utilizzando un sistema che tiene conto della gravità delle manifestazioni, secondo la scala di seguito riportata. 20 healthy volunteers of both sexes between the ages of 18 and 60 were recruited. The sample was placed in aluminum Finn Chambers (Bracco) which were applied to the skin of the back and / or porous patches which were applied to the skin of the forearm. The application of the product on the skin lasted 24 hours. Skin reactions were clinically assessed 30 minutes and 24 hours after Finn Chamber removal and 30 minutes and 24 hours after porous patch removal and were interpreted using a system that takes into account the severity of the manifestations, according to the scale below. .
Scala di valutazione delle reazioni cutanee: Skin reaction rating scale:
0= assenza di eritema; 0 = absence of erythema;
0,5= eritema minimo o incerto 0.5 = minimal or uncertain erythema
1 = leggero rossore a macchie e diffuso; 1 = slight diffuse and blotchy redness;
2 = rossore moderato, uniforme 2 = moderate, uniform redness
3 = forte rossore uniforme 3 = strong uniform redness
4 = rossore bruciante 4 = burning redness
0= assenza di edema; 0 = absence of edema;
1 = edema molto leggero (appena visibile); 1 = very slight edema (barely visible);
2 = edema leggero( contorni ben visibile); 2 = slight edema (clearly visible contours);
3 = edema moderato 3 = moderate edema
4 = edema forte (tumefazione estesa oltre l’area di applicazione) 4 = severe edema (swelling extended beyond the application area)
Classificazione dell’indice di irritazione medio: Classification of the average irritation index:
<0,5 = non irritante <0.5 = non-irritating
0,5 – 1 = leggermente irritante 0.5 â € “1 = slightly irritating
1,0 – 3 = moderatamente irritante 1.0 - 3 = moderately irritating
≥ 3 = fortemente irritante â ‰ ¥ 3 = strongly irritating
La composizione dell’invenzione à ̈ risultata non irritante , con indice medio di irritazione dopo 30 min dalla rimozione del patch o della camera pari a 0,00 e opo 24 ore dalla rimozione del patch o della camera 0,00. The composition of the invention was found to be non-irritating, with an average index of irritation after 30 min from removal of the patch or chamber equal to 0.00 and after 24 hours from removal of the patch or chamber 0.00.
2. VALUTAZIONE DELL’EFFETTO DELLA COMPOSIZIONE DELL’INVENZIONE SU PAZIENTI CON PIAGHE DA DECUBITO A STADIO 1 2. EVALUATION OF THE EFFECT OF THE COMPOSITION OF THE INVENTION ON PATIENTS WITH DECUBITUS SHEETS AT STAGE 1
Sono stati trattati 50 pazienti informati ospedalizzati con piaghe da decubito di tipo 1 ed à ̈ stata valutata trattando i pazienti per un tempo compreso tra 3 e 10 giorni, in media una settimana. 50 hospitalized informed patients with type 1 pressure ulcers were treated and was assessed by treating patients for 3 to 10 days, averaging one week.
In questi 50 pazienti, maschi e femmine di età variabile ma tutti presentanti piaghe da decubito di tipo 1, il trattamento con la composizione dell’invenzione ha portato alla miglioramento delle condizioni cutanee o al non peggioramento delle stesse nel 94% dei casi analizzati, e si à ̈ osservato un peggioramento della situazione della cute solamente nel 6% dei casi. In these 50 patients, males and females of variable age but all presenting with type 1 bedsores, the treatment with the composition of the invention led to the improvement of the skin conditions or to the non-worsening of the same in 94% of the cases analyzed, and a worsening of the skin situation was observed in only 6% of cases.
In totale, i casi in cui si à ̈ osservato miglioramento della situazione cutanea sono stati il 42%. In total, the cases in which improvement in the skin situation was observed were 42%.
Nel 36% dei casi si à ̈ osservata senza ombra di dubbio la regressione delle piaghe di tipo 1 a cute non iperemica. Regression of type 1 sores to non-hyperemic skin was undoubtedly observed in 36% of cases.
3. TEST COMPARATIVO TRA TRATTAMENTO CON LA COMPOSIZIONE DELL’INVENZIONE E TRATTAMENTO CON COMPOSIZIONI COMPRENDENTI OSSIDO DI ZINCO SU PAZIENTI CON PIAGHE DA DECUBITO A STADIO 1 3. COMPARATIVE TEST BETWEEN TREATMENT WITH THE COMPOSITION OF THE INVENTION AND TREATMENT WITH COMPOSITIONS INCLUDING ZINC OXIDE ON PATIENTS WITH DECUBITUS SHEETS AT STAGE 1
Sono stati-valutati stesa tipologia di pazienti analizzati sopra per il prodotto, ma il miglioramento à ̈ stato del 20% vs il 42% di quelli trattati con il prodotto. Il 78% sono risultati stazionari e il 2% sono peggiorati. The same type of patients analyzed above were evaluated for the product, but the improvement was 20% vs 42% of those treated with the product. 78% were stationary and 2% worsened.
Claims (20)
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000121A ITRM20120121A1 (en) | 2012-03-27 | 2012-03-27 | DERMOPROTECTIVE AND DERMO-BALANCING COMPOSITION. |
HUE13722547A HUE032878T2 (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
DK13722547.0T DK2830587T3 (en) | 2012-03-27 | 2013-03-27 | THERMO PROTECTIVE AND DERMOBALANCING COMPOSITION |
PCT/IB2013/052433 WO2013144861A2 (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
RS20170716A RS56379B1 (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
PL13722547T PL2830587T3 (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
LTEP13722547.0T LT2830587T (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
EP13722547.0A EP2830587B1 (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
SI201330722T SI2830587T1 (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
ES13722547.0T ES2629930T3 (en) | 2012-03-27 | 2013-03-27 | Dermoprotective and Dermoebalancing Composition |
US14/389,040 US10369181B2 (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
PT137225470T PT2830587T (en) | 2012-03-27 | 2013-03-27 | Dermo-protective and dermo-balancing composition |
HRP20171059TT HRP20171059T1 (en) | 2012-03-27 | 2017-07-11 | Dermo-protective and dermo-balancing composition |
CY20171100797T CY1119117T1 (en) | 2012-03-27 | 2017-07-26 | Dermatoprosthetic and skin-balancing composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000121A ITRM20120121A1 (en) | 2012-03-27 | 2012-03-27 | DERMOPROTECTIVE AND DERMO-BALANCING COMPOSITION. |
Publications (1)
Publication Number | Publication Date |
---|---|
ITRM20120121A1 true ITRM20120121A1 (en) | 2013-09-28 |
Family
ID=46584147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT000121A ITRM20120121A1 (en) | 2012-03-27 | 2012-03-27 | DERMOPROTECTIVE AND DERMO-BALANCING COMPOSITION. |
Country Status (14)
Country | Link |
---|---|
US (1) | US10369181B2 (en) |
EP (1) | EP2830587B1 (en) |
CY (1) | CY1119117T1 (en) |
DK (1) | DK2830587T3 (en) |
ES (1) | ES2629930T3 (en) |
HR (1) | HRP20171059T1 (en) |
HU (1) | HUE032878T2 (en) |
IT (1) | ITRM20120121A1 (en) |
LT (1) | LT2830587T (en) |
PL (1) | PL2830587T3 (en) |
PT (1) | PT2830587T (en) |
RS (1) | RS56379B1 (en) |
SI (1) | SI2830587T1 (en) |
WO (1) | WO2013144861A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700082270A1 (en) * | 2017-07-19 | 2019-01-19 | Ricciuti Laura | NEW COMPOSITION MYORLASSANT AND CICATRIZING |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU630561B2 (en) * | 1990-06-12 | 1992-10-29 | Cathy Palou | A therapeutic preparation containing myrrh for treating skin disorders |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US20040156873A1 (en) * | 2003-02-10 | 2004-08-12 | Gupta Shyam K. | Topically Bioavailable Acne and Rosacea Treatment Compositions |
US20060172022A1 (en) * | 2005-01-31 | 2006-08-03 | Sharon Szanzer | Skin treating salve composition |
US20070269537A1 (en) * | 2003-02-10 | 2007-11-22 | Bioderm Research | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System |
CN101129678A (en) * | 2007-09-05 | 2008-02-27 | 杨丕良 | Externally used formulated product for treating empyrosis and method of preparing the same |
US20090042846A1 (en) * | 2005-08-19 | 2009-02-12 | Bioderm Research | Topical Delivery System for Phytosterols |
WO2011054090A1 (en) * | 2009-11-03 | 2011-05-12 | Nutriquine N.V. | Compositions comprising extracts of boswellia, tea tree, aloe and lavender oil and methods of treating wounds, burns and skin injuries therewith |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070003536A1 (en) * | 2000-11-21 | 2007-01-04 | Zimmerman Amy C | Topical skin compositions, their preparation, and their use |
US20040105873A1 (en) * | 2002-11-29 | 2004-06-03 | Gupta Shyam K. | Topical formulation including stabilized water-soluble and oil-soluble compositions |
CA2684601C (en) * | 2007-04-19 | 2014-04-29 | Mary Kay Inc. | Cosmetic methods of treating skin with magnolia and citrus grandis extracts containing compositions |
-
2012
- 2012-03-27 IT IT000121A patent/ITRM20120121A1/en unknown
-
2013
- 2013-03-27 LT LTEP13722547.0T patent/LT2830587T/en unknown
- 2013-03-27 RS RS20170716A patent/RS56379B1/en unknown
- 2013-03-27 SI SI201330722T patent/SI2830587T1/en unknown
- 2013-03-27 PL PL13722547T patent/PL2830587T3/en unknown
- 2013-03-27 EP EP13722547.0A patent/EP2830587B1/en active Active
- 2013-03-27 PT PT137225470T patent/PT2830587T/en unknown
- 2013-03-27 US US14/389,040 patent/US10369181B2/en active Active
- 2013-03-27 HU HUE13722547A patent/HUE032878T2/en unknown
- 2013-03-27 DK DK13722547.0T patent/DK2830587T3/en active
- 2013-03-27 WO PCT/IB2013/052433 patent/WO2013144861A2/en active Application Filing
- 2013-03-27 ES ES13722547.0T patent/ES2629930T3/en active Active
-
2017
- 2017-07-11 HR HRP20171059TT patent/HRP20171059T1/en unknown
- 2017-07-26 CY CY20171100797T patent/CY1119117T1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU630561B2 (en) * | 1990-06-12 | 1992-10-29 | Cathy Palou | A therapeutic preparation containing myrrh for treating skin disorders |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US20040156873A1 (en) * | 2003-02-10 | 2004-08-12 | Gupta Shyam K. | Topically Bioavailable Acne and Rosacea Treatment Compositions |
US20070269537A1 (en) * | 2003-02-10 | 2007-11-22 | Bioderm Research | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System |
US20060172022A1 (en) * | 2005-01-31 | 2006-08-03 | Sharon Szanzer | Skin treating salve composition |
US20090042846A1 (en) * | 2005-08-19 | 2009-02-12 | Bioderm Research | Topical Delivery System for Phytosterols |
CN101129678A (en) * | 2007-09-05 | 2008-02-27 | 杨丕良 | Externally used formulated product for treating empyrosis and method of preparing the same |
WO2011054090A1 (en) * | 2009-11-03 | 2011-05-12 | Nutriquine N.V. | Compositions comprising extracts of boswellia, tea tree, aloe and lavender oil and methods of treating wounds, burns and skin injuries therewith |
Non-Patent Citations (1)
Title |
---|
"Myrrh", 1 February 2012 (2012-02-01), XP055051064, Retrieved from the Internet <URL:http://www.herbs2000.com/herbs/herbs_myrrh.htm> [retrieved on 20130124] * |
Also Published As
Publication number | Publication date |
---|---|
CY1119117T1 (en) | 2018-02-14 |
HRP20171059T1 (en) | 2017-10-06 |
PT2830587T (en) | 2017-06-30 |
PL2830587T3 (en) | 2017-09-29 |
EP2830587A2 (en) | 2015-02-04 |
US10369181B2 (en) | 2019-08-06 |
DK2830587T3 (en) | 2017-07-10 |
LT2830587T (en) | 2017-09-11 |
RS56379B1 (en) | 2017-12-29 |
WO2013144861A3 (en) | 2014-03-06 |
WO2013144861A2 (en) | 2013-10-03 |
SI2830587T1 (en) | 2017-08-31 |
ES2629930T3 (en) | 2017-08-16 |
EP2830587B1 (en) | 2017-05-03 |
US20150064272A1 (en) | 2015-03-05 |
HUE032878T2 (en) | 2017-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008140200A1 (en) | External compositions for the skin | |
US9931366B2 (en) | Topical pharmaceutical bases for wound and scar treatment | |
EP2364713B1 (en) | Dermatological composition for use in the treatment of skin burns, skin diseases and infected wounds | |
US6419963B1 (en) | Composition and method for the treatment of diaper rash using natural products | |
DK2575973T3 (en) | TAMARED SEED POLYSACCHARIDE AND FERULA HERMONIS EXTRACT USED IN TREATMENT OF INFLAMMATORY DISEASES | |
WO2014167552A1 (en) | Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations | |
ITRM20120121A1 (en) | DERMOPROTECTIVE AND DERMO-BALANCING COMPOSITION. | |
EP2570124B1 (en) | Oleuropein compositions for healing wounds and ulcers in elderly people and/or diabetics | |
JP2024517225A (en) | Topical Compositions Containing Manuka Oil and Palmarosa Oil for Treating Skin Conditions - Patent application | |
US20040131704A1 (en) | A method of organic and all natural treatment, prevention and relief of diaper dermatitis and other related skin irritations. | |
ES2613950T3 (en) | Oleuropein compositions for wound healing and ulcers in the elderly and / or diabetics | |
CN107072979B (en) | Use of flavonoid compounds for preparing wound healing compositions | |
EP3506876B1 (en) | Composition for nail fungus | |
US20140127315A1 (en) | Caudal Salve | |
SHAIKH et al. | Traditional remedies for wound healing: a review | |
US20110243856A1 (en) | Permeable Mixtures, Methods and Compositions for the Skin | |
CN107683144B (en) | Combination of at least one protease inhibitor and at least one active ingredient for use in the prevention and/or treatment of skin lesions | |
Khan et al. | Formulation and evaluation of derma heal cream against wound and burn healing activity in streptozotocin-induced diabetic Wistar albino rat | |
Makdisi et al. | Oats and skin health | |
MICHELLE et al. | Skin Barrier Repair | |
EP3006035A1 (en) | Cicatrizing composition for the treatment and resolution of external lesions | |
WO2022139746A2 (en) | Composition containing natural vegetable oils and skin care product comprising said composition | |
KR20230057788A (en) | A composition to remove or to relieve bruise | |
ITRM20120174A1 (en) | NEW COMPOSITIONS FOR THE TREATMENT OF CHRONIC WOUNDS. | |
WO2024073011A1 (en) | Topical compositions and methods for the treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation |